(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
The Drone Video of the Year is stunning – you've not seen Namibia like this- Extravagance SUVs for Seniors: Solace, Innovation, and Security
- Most loved Well known Accessory Styles For 2024
- Spain breaks jobs record with 22 million Social Security contributors
- Israeli Chief of Staff declares new border with Gaza Strip
- Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Israeli media reports Iran attacking greater Tel Aviv region
